199 related articles for article (PubMed ID: 25090024)
1. Multi-agent chemotherapy overcomes glucocorticoid resistance conferred by a BIM deletion polymorphism in pediatric acute lymphoblastic leukemia.
Soh SX; Lim JY; Huang JW; Jiang N; Yeoh AE; Ong ST
PLoS One; 2014; 9(8):e103435. PubMed ID: 25090024
[TBL] [Abstract][Full Text] [Related]
2. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.
Ng KP; Hillmer AM; Chuah CT; Juan WC; Ko TK; Teo AS; Ariyaratne PN; Takahashi N; Sawada K; Fei Y; Soh S; Lee WH; Huang JW; Allen JC; Woo XY; Nagarajan N; Kumar V; Thalamuthu A; Poh WT; Ang AL; Mya HT; How GF; Yang LY; Koh LP; Chowbay B; Chang CT; Nadarajan VS; Chng WJ; Than H; Lim LC; Goh YT; Zhang S; Poh D; Tan P; Seet JE; Ang MK; Chau NM; Ng QS; Tan DS; Soda M; Isobe K; Nöthen MM; Wong TY; Shahab A; Ruan X; Cacheux-Rataboul V; Sung WK; Tan EH; Yatabe Y; Mano H; Soo RA; Chin TM; Lim WT; Ruan Y; Ong ST
Nat Med; 2012 Mar; 18(4):521-8. PubMed ID: 22426421
[TBL] [Abstract][Full Text] [Related]
3. The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia.
Ko TK; Chin HS; Chuah CT; Huang JW; Ng KP; Khaw SL; Huang DC; Ong ST
Oncotarget; 2016 Jan; 7(3):2721-33. PubMed ID: 26517680
[TBL] [Abstract][Full Text] [Related]
4. Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells.
Jing D; Bhadri VA; Beck D; Thoms JA; Yakob NA; Wong JW; Knezevic K; Pimanda JE; Lock RB
Blood; 2015 Jan; 125(2):273-83. PubMed ID: 25336632
[TBL] [Abstract][Full Text] [Related]
5. Bim polymorphisms: influence on function and response to treatment in children with acute lymphoblastic leukemia.
Gagné V; Rousseau J; Labuda M; Sharif-Askari B; Brukner I; Laverdière C; Ceppi F; Sallan SE; Silverman LB; Neuberg D; Kutok JL; Sinnett D; Krajinovic M
Clin Cancer Res; 2013 Sep; 19(18):5240-9. PubMed ID: 23908358
[TBL] [Abstract][Full Text] [Related]
6. The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer.
Zhao M; Zhang Y; Cai W; Li J; Zhou F; Cheng N; Ren R; Zhao C; Li X; Ren S; Zhou C; Hirsch FR
Cancer; 2014 Aug; 120(15):2299-307. PubMed ID: 24737648
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.
Bachmann PS; Piazza RG; Janes ME; Wong NC; Davies C; Mogavero A; Bhadri VA; Szymanska B; Geninson G; Magistroni V; Cazzaniga G; Biondi A; Miranda-Saavedra D; Göttgens B; Saffery R; Craig JM; Marshall GM; Gambacorti-Passerini C; Pimanda JE; Lock RB
Blood; 2010 Oct; 116(16):3013-22. PubMed ID: 20647567
[TBL] [Abstract][Full Text] [Related]
8. Glucocorticoid-mediated BIM induction and apoptosis are regulated by Runx2 and c-Jun in leukemia cells.
Heidari N; Miller AV; Hicks MA; Marking CB; Harada H
Cell Death Dis; 2012 Jul; 3(7):e349. PubMed ID: 22825467
[TBL] [Abstract][Full Text] [Related]
9. FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors.
Kiyota M; Kuroda J; Yamamoto-Sugitani M; Shimura Y; Nakayama R; Nagoshi H; Mizutani S; Chinen Y; Sasaki N; Sakamoto N; Kobayashi T; Matsumoto Y; Horiike S; Taniwaki M
Apoptosis; 2013 Nov; 18(11):1437-1446. PubMed ID: 23851982
[TBL] [Abstract][Full Text] [Related]
10. Divergent mechanisms of glucocorticoid resistance in experimental models of pediatric acute lymphoblastic leukemia.
Bachmann PS; Gorman R; Papa RA; Bardell JE; Ford J; Kees UR; Marshall GM; Lock RB
Cancer Res; 2007 May; 67(9):4482-90. PubMed ID: 17483364
[TBL] [Abstract][Full Text] [Related]
11. The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors.
Lee JY; Ku BM; Lim SH; Lee MY; Kim H; Kim M; Kim S; Jung HA; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2015 Jun; 10(6):903-9. PubMed ID: 26001141
[TBL] [Abstract][Full Text] [Related]
12. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.
Nakagawa T; Takeuchi S; Yamada T; Ebi H; Sano T; Nanjo S; Ishikawa D; Sato M; Hasegawa Y; Sekido Y; Yano S
Cancer Res; 2013 Apr; 73(8):2428-34. PubMed ID: 23382048
[TBL] [Abstract][Full Text] [Related]
13. The effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy.
Ying HQ; Chen J; He BS; Pan YQ; Wang F; Deng QW; Sun HL; Liu X; Wang SK
Sci Rep; 2015 Jun; 5():11348. PubMed ID: 26076815
[TBL] [Abstract][Full Text] [Related]
14. The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia.
Rauzan M; Chuah CT; Ko TK; Ong ST
PLoS One; 2017; 12(3):e0174107. PubMed ID: 28301600
[TBL] [Abstract][Full Text] [Related]
15. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
Hall CP; Reynolds CP; Kang MH
Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
[TBL] [Abstract][Full Text] [Related]
16. Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer.
Lee JH; Lin YL; Hsu WH; Chen HY; Chang YC; Yu CJ; Shih JY; Lin CC; Chen KY; Ho CC; Laio WY; Yang PC; Yang JC
J Thorac Oncol; 2014 Sep; 9(9):1385-92. PubMed ID: 25057939
[TBL] [Abstract][Full Text] [Related]
17. Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak.
Melarangi T; Zhuang J; Lin K; Rockliffe N; Bosanquet AG; Oates M; Slupsky JR; Pettitt AR
Cell Death Dis; 2012 Aug; 3(8):e372. PubMed ID: 22898870
[TBL] [Abstract][Full Text] [Related]
18. Erg and AP-1 as determinants of glucocorticoid response in acute lymphoblastic leukemia.
Chen DW; Saha V; Liu JZ; Schwartz JM; Krstic-Demonacos M
Oncogene; 2013 Jun; 32(25):3039-48. PubMed ID: 22869147
[TBL] [Abstract][Full Text] [Related]
19. MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM.
Rambal AA; Panaguiton ZL; Kramer L; Grant S; Harada H
Leukemia; 2009 Oct; 23(10):1744-54. PubMed ID: 19404317
[TBL] [Abstract][Full Text] [Related]
20. The BCL2 rheostat in glucocorticoid-induced apoptosis of acute lymphoblastic leukemia.
Ploner C; Rainer J; Niederegger H; Eduardoff M; Villunger A; Geley S; Kofler R
Leukemia; 2008 Feb; 22(2):370-7. PubMed ID: 18046449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
